PR Newswire: news distribution, targeting and monitoring
33.21 USD  +0.19 (+0.58%)
Official Closing Price  /  Updated: 6:40 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(HAE) Community Analysis from
April 18, 2014
(Stock Blog Hub, 1/14/13)
2013 is considered a landmark year for Haemonetics (HAE) based on several key growth factors, including entry in the $1.2 billion whole blood collection market with the acquisition of the...(read more)
(Stock Blog Hub, 6/16/11)
ViroPharma Inc. (VPHM) recently announced that the European Commission (EC) granted Centralized Marketing Authorization to Cinryze for the treatment of hereditary angioedema (HAE). The...(read more)
(Benzinga, 11/2/10)
Haemonetics Corporation (NYSE: HAE) reported 2Q earnings that leads Morgan Keegan to believe that fiscal 3Q is expected to be the low-point in the company's sales cycle. In the report, Morgan Keegan writes "Haemonetics reported fiscal...(read more)
Haemonetics (HAE) Company Overview

Haemonetics was founded in 1971 and became publicly owned in 1979. A division of American Hospital Supply Corporation, and then DuPont in 1985, the company completed its Initial Public Offering in 1991, with Du Pont divesting its remaining interest. The company is the market leader in developing and manufacturing blood collection and processing technology to help ensure a safe and adequate blood supply. The company manufactures automated systems and single use consumables used in blood donation, blood processing, and surgical salvage of blood. Haemonetics' customers are blood banks and plasma collectors, hospitals and hospital service providers. The American Red Cross is its largest customer. In 2004, the company reorganized into two product groups to address the blood donor and surgical patient markets. In Donor Products, the company offers automated plasma and platelet collection systems, as well as processing systems to freeze, thaw and wash red blood cells. The company also contract manufactures sterile I.V. solutions for pharmaceutical customers. In Patient Products, the company offers surgical blood salvage systems that are used to collect the patient's own blood that is then reused rather than lost. Haemonetics also markets data management systems through their 5D Information Systems subsidiary to promote efficient and compliant operations of blood collection vendors. The company operates in the U.S., Europe and Asia, including Japan. Haemonetics markets its products in more than 50 countries, using a direct sales force as well as some independent distributors, totaling 1,826 full time employees. In fiscal 2007, the company generated $449.6 million in revenues, with roughly 43% of revenues generated in the U.S. and the remainder internationally. Principally, Japan accounted for about 20% of fiscal 2007 revenues and Europe contributed about 28% to fiscal 2007 revenues.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

Online Member Center

Not a Member?
Click Here to Join
Search News Releases
Advanced Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release